M. Mcdermott

Romosozumab and antiresorptive treatment: the importance of treatment sequence

E. Lewiecki, C. Libanati, D. Kendler, 2022, Osteoporosis International.

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids

Stanley B. Cohen, P. Geusens, W. Lems, 2021, Arthritis & rheumatology.

Estimation of Long‐Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX‐ and Virtual Twin‐Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials

J. Kanis, E. Siris, N. Pannacciulli, 2020, JBMR plus.

A Pooled Analysis of Fall Incidence From Placebo‐Controlled Trials of Denosumab

S. Cummings, R. Eastell, E. McCloskey, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Initial 17β‐Estradiol Dose for Treating Vasomotor Symptoms

J. Lenihan, M. Notelovitz, J. Arce, 2000, Obstetrics and gynecology.

A systematic review on the effectiveness of continuity of care and its role in patient satisfaction and decreased hospital readmissions in the adult patient receiving home care services.

J. Slyer, J. Singleton, M. Mcdermott, 2012 .

Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women

S. Silverman, M. Bonafede, S. Gandra, 2021, Osteoporosis International.

Updated trabecular bone score accounting for the soft tissue thickness (TBSTT) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis

E. Shevroja, D. Hans, Shuang Huang, 2022, Osteoporosis International.